Research & Clinical Evidence
Cognitive Leap® is committed to evidence-based development. Our solutions undergo rigorous clinical validation, with results published and presented at leading academic institutions.
Completed Studies
Stanford Neurodiversity Summit 2024
n=58 • Location: Cogleap® US centers (Irvine, Palo Alto) • Population: Children ages 5-18 with ADHD/ASD
Key Insights:
ASD Differential Response Study 2025
n=33 • Focus: Neurotype-specific treatment response
Key Insights:
Sun Yat-sen University RCT 2025
n=100 • Design: Randomized controlled trial • Location: Sun Yat-sen University, Shenzhen
Key Insights:
US Clinic Outcomes Report — February 2026
n=49 • Location: Cogleap® centers in Irvine and Palo Alto, CA • Population: Children ages 4-18 (55% ASD, 8% ADHD, 14% ASD+ADHD)
Key Insights:
Academic Relationships
Stanford Medicine
Advisor relationship, outcomes presented at
Neurodiversity Summit 2024
Duke University
Global testing partnership for assessment validation
Palo Alto University
Practicum site for clinical psychology training
Sun Yat-sen University
Formal clinical trial partnership, School of Public Health
